FDA approves gene therapy to treat a rare cancer | Science News

ADVERTISEMENT

MISSION CRITICAL

Support credible science journalism.

Subscribe to Science News today.



Science Ticker

Your daily roundup of research news

Science News Staff
Science Ticker

FDA approves gene therapy to treat a rare cancer

T cells

A gene therapy treatment called CAR-T immunotherapy has been approved for use in a rare type of leukemia. Immune cells called T cells (shown) are engineered to seek and destroy specific types of cancer.

Sponsor Message

On August 30, the U.S. Food and Drug Administration approved a novel gene therapy for patients with a rare type of leukemia. This is the first time the agency has greenlighted a gene therapy approach for use in the United States.

The treatment, called CAR-T immunotherapy, uses genetically engineered T cells, immune system fighters usually tasked with identifying invaders in the body, such as bacteria, viruses or foreign cells. The engineered cells, called CAR-T cells, are customized for each patient. An individual’s T cells are collected and altered in the lab to carry a new gene that directs the T cells to attack certain cancer cells. Those modified T cells are injected back into the patient to seek out and destroy the cancer.

CAR-T cell therapy has shown promise in fighting a type of cancer called B-cell acute lymphoblastic leukemia, or ALL, which can strike children and adults. Several CAR-T approaches are in the works, including an experimental therapy that made headlines in 2015 when it was used in England to treat a 1-year-old girl with leukemia.

The FDA approved an approach to CAR-T therapy manufactured by Novartis Pharmaceuticals, called Kymriah. The approval applies to children and young adults (up to age 25) with B-cell ALL that doesn’t respond to treatment or has relapsed.

Get Science News headlines by e-mail.

More Body & Brain articles